Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
| ▸ | CBLB | Q13191 | 7/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945906 | 0.91 | MAP3K5 (0.55) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL945460 | 0.84 | MAP3K5 (0.55) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL934738 | 0.84 | MAP3K5 (0.51) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL1083684 | 0.82 | TP53BP1 (0.48) | MAP3K5SMN1; SMN2RAF1BRAFTP53BP1 | |
| SCHEMBL943582 | 0.81 | LMNA (0.63) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL944106 | 0.81 | LMNA (0.60) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL952892 | 0.80 | LMNA (0.64) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL946100 | 0.78 | LMNA (0.56) | LMNAGAAMAP3K5CLK1SMN1; SMN2 | |
| SCHEMBL22739096 | 0.78 | MAP3K5 (0.66) | LMNAGAAMAP3K5TP53BP1CBLB | |
| SCHEMBL27872965 | 0.78 | AGXT (0.44) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | claimed |
| EP-3363797-A1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2933252-B1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES INC (US) | 2018-01-03 | — | — | EP | claimed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | claimed |
| EP-2933252-A1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-10-21 | — | — | EP | claimed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | claimed |
| EP-2454250-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-01-14 | — | — | EP | claimed |
| CN-102482257-A | Apoptosis signal-modulating kinase inhibitors | GILEAD SCIENCES INC | 2012-05-30 | — | — | CN | claimed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | claimed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| CN-102482257-A | Apoptosis signal-modulating kinase inhibitors | GILEAD SCIENCES INC | 2012-05-30 | — | — | CN | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | LMNA 1002/4885GAA 2819/4885MAP3K5 16/4885 |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BRD4, JAK2, JAK1 | LMNA 4226/4885GAA 2901/4885MAP3K5 105/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | LMNA 1056/4885GAA 2978/4885MAP3K5 16/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | LMNA 1056/4885GAA 2978/4885MAP3K5 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.